Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available

Pharmacoepidemiol Drug Saf. 2017 May;26(5):597-599. doi: 10.1002/pds.4177. Epub 2017 Feb 15.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disclosure*
  • Drug Approval
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Humans
  • Patient Care / standards*
  • United States
  • United States Food and Drug Administration